Imagion Biosystems Limited
IBXXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.20 | -0.32 | 0.29 |
| FCF Yield | -50.00% | -19.81% | -5.60% | -14.68% |
| EV / EBITDA | -3.88 | -4.73 | -17.35 | -4.04 |
| Quality | ||||
| ROIC | -134.06% | -701.61% | -130.76% | -62.26% |
| Gross Margin | 84.95% | -5.63% | -17.74% | 5.31% |
| Cash Conversion Ratio | 0.61 | 0.67 | 0.89 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.61% | 20.29% | 146.23% | 90.84% |
| Free Cash Flow Growth | 85.06% | 7.62% | -74.16% | -14.17% |
| Safety | ||||
| Net Debt / EBITDA | -0.25 | -0.56 | -0.02 | 2.38 |
| Interest Coverage | -0.66 | -14.02 | -6,115.43 | -1,932.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 11.47 | 15.49 |
| Cash Conversion Cycle | -1,887.74 | -105.13 | 9.99 | -30.24 |